Veracyte, Inc. (VCYT) on Decifer

Decifer ranks VCYT number 63 of 270 tracked names on durable business quality.

Why it ranks here

• Its returns on invested money are modest, around 5% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 16% a year and profits grew 162% over the past year.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• We do not have a clean read on how it is run yet.
• The only credible molecular diagnostics supplier in a partly recognized system with profits up 162%, but modest 5% returns and momentum of 7 out of 35 cap it.

The current read

The evidence on VCYT lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Genomic Medicine & Precision Diagnostics: The collapsing cost of DNA/RNA sequencing and validation of genomic classifiers is moving clinical practice toward routine molecular diagnostics and companion testing.

Read the full VCYT research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.